Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Weixue Huang

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Journal of Medicinal Chemistry|May 10, 2024
Discovery of <b>LLC355</b> as an Autophagy-Tethering Compound for the Degradation of Discoidin Domain Receptor 1Lianchao Liu, Lijie Zhao, Lujun Yang, et al.
Journal of Medicinal Chemistry|April 30, 2024
Discovery of LLC0424 as a Potent and Selective <i>in Vivo</i> NSD2 PROTAC DegraderLianchao Liu, Abhijit Parolia, Yihan Liu, et al.
Journal of the American Chemical Society|March 28, 2025
<i>O</i>-Cyanobenzaldehydes Irreversibly Modify Both Buried and Exposed Lysine Residues in Live CellsHuan Ling, Lin Li, Liping Duan, et al.
European Journal of Medicinal Chemistry|November 9, 2024
Discovery of the first selective and potent PROTAC degrader for the pseudokinase TRIB2Chaowei Wen, Prathibha R Gajjala, Yihan Liu, et al.
Journal of Medicinal Chemistry|August 8, 2022
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13Jianzhang Yang, Yu Chang, Jean Ching-Yi Tien, et al.
Journal of Medicinal Chemistry|October 10, 2024
Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC DegraderLicheng Zhou, Kaijie Zhou, Yu Chang, et al.
Journal of Medicinal Chemistry|March 13, 2025
Discovery of <b>YJZ5118</b>: A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt InhibitionJianzhang Yang, Yu Chang, Kaijie Zhou, et al.
Journal of Medicinal Chemistry|June 8, 2026
Structure-Based Design and Optimization of Novel, Potent and Selective Covalent FGFR2/3 Inhibitors with a Tricyclic CoreXuzhi Lu, Zhaodi Tian, Xueqiang Li, et al.
Cell Reports. Medicine|October 1, 2024
Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibitionYu Chang, Xiaoju Wang, Jianzhang Yang, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Journal of Medicinal Chemistry|May 10, 2024
Discovery of <b>LLC355</b> as an Autophagy-Tethering Compound for the Degradation of Discoidin Domain Receptor 1Lianchao Liu, Lijie Zhao, Lujun Yang, et al.
Journal of Medicinal Chemistry|April 30, 2024
Discovery of LLC0424 as a Potent and Selective <i>in Vivo</i> NSD2 PROTAC DegraderLianchao Liu, Abhijit Parolia, Yihan Liu, et al.
Journal of the American Chemical Society|March 28, 2025
<i>O</i>-Cyanobenzaldehydes Irreversibly Modify Both Buried and Exposed Lysine Residues in Live CellsHuan Ling, Lin Li, Liping Duan, et al.
European Journal of Medicinal Chemistry|November 9, 2024
Discovery of the first selective and potent PROTAC degrader for the pseudokinase TRIB2Chaowei Wen, Prathibha R Gajjala, Yihan Liu, et al.
Journal of Medicinal Chemistry|August 8, 2022
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13Jianzhang Yang, Yu Chang, Jean Ching-Yi Tien, et al.
Journal of Medicinal Chemistry|October 10, 2024
Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC DegraderLicheng Zhou, Kaijie Zhou, Yu Chang, et al.
Journal of Medicinal Chemistry|March 13, 2025
Discovery of <b>YJZ5118</b>: A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt InhibitionJianzhang Yang, Yu Chang, Kaijie Zhou, et al.
Journal of Medicinal Chemistry|June 8, 2026
Structure-Based Design and Optimization of Novel, Potent and Selective Covalent FGFR2/3 Inhibitors with a Tricyclic CoreXuzhi Lu, Zhaodi Tian, Xueqiang Li, et al.
Cell Reports. Medicine|October 1, 2024
Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibitionYu Chang, Xiaoju Wang, Jianzhang Yang, et al.
Pageof 4